Skip to main content
SpringerLink
Log in

The Epidemiology of Pain and Opioid Abuse

  • Chapter
  • First Online:
Treating Comorbid Opioid Use Disorder in Chronic Pain

  • 985 Accesses

Abstract

The interconnected nature of the analgesic and pleasurable effects of opioid drugs has made their use and abuse a significant public health concern. Due to the possibility of opioid abuse resulting from medical treatment, there has been significant effort to determine the comorbidity of chronic pain conditions and opioid abuse. Previous efforts have been plagued by a lack of relevant data and poor methodological consistency across investigations. However, efforts to better define the behaviors involved in opioid misuse and abuse have led to more valid and reliable estimates. Rates of what are now defined as “aberrant opioid use behaviors” and “misuse” among pain patients range from 11.5 to 29.0 %. Rates of the more severe phenomenon of “abuse” and “addiction” range from 3.3 to 12.0 %. Clinicians are tasked with balancing adequate pain management using opioids with their risk of abuse. Continued research in the comorbidity of these two conditions will hopefully result in data that clinicians can use to circumvent the development of addiction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kapoor LD. Opium poppy—botany, chemistry, and pharmacology. Binghamton: Haworth Press; 1995. p. 1–17.

    Google Scholar 

  2. Bernard MC. Experimental researches on opium and its alkaloids. Boston Med Surg J. 1865;72:349–57.

    Article  Google Scholar 

  3. Schiff PL. Opium and its alkaloids. Am J Pharmaceutical Ed. 2002;66:186–94.

    Google Scholar 

  4. Brownstein MJ. Review A, brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993;90:5391–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67–116.

    Google Scholar 

  6. Manchikanti L, Helm 2nd S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.

    PubMed  Google Scholar 

  7. Bertalmio AJ, Woods JH. Reinforcing effect ofalfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J Pharmacol Exp Ther. 1980;251:455–60.

    Google Scholar 

  8. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL.Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383(6603):819–23.

    Google Scholar 

  9. Negus SS, Henriksen SJ, Mattox A, Pasternak GW, Portoghese PS, Takemori AE, Weinger MB, Koob GF. Effect of antagonists selective for mu,delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther. 1993;265:1245–52.

    Google Scholar 

  10. United Nations Office on Drugs and Crime, World Drug Report 2014 (United Nations publication, Sales No. E.14.XI.

    Google Scholar 

  11. European Monitoring Centre for Drugs Addiction (EMCDA), 2014: European Drug Report 2014: Trends and developments. http://www.emcdda.europa.eu/publications/edr/trends-developments/2014. Accessed April 16, 2015.

  12. Substance Abuse and Mental Health Services Administration. Results from the 2013 National survey on drug use and health: summary of national findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville: Substance Abuse and Mental Health Services Administration; 2014.

    Google Scholar 

  13. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33:1179–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O’Brien C, O’Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 2012;153(12): 2315–24.

    Google Scholar 

  15. Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol. 2014;20(4):784–98. doi:10.1111/adb.12163.

    Article  PubMed  Google Scholar 

  16. O’Connor AB, Turk DC, Dworkin RH, Katz NP, Colucci R, Haythornthwaite JA, Klein M, O’Brien C, Posner K, Rappaport BA, Reisfield G, Adams EH, Balster RL, Bigelow GE, Burke LB, Comer SD, Cone E, Cowan P, Denisco RA, Farrar JT, Foltin RW, Haddox JD, Hertz S, Jay GW, Junor R, Kopecky EA, Leiderman DB, McDermott MP, Palmer PP, Raja SN, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Smith SM, Sokolowska M, Stauffer JW, Walsh SL, Zacny JP. Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain 2013;154(11): 2324-34.

    Google Scholar 

  17. Global Industry Analysts, Inc. Report, January 10, 2011. http://www.prweb.com/pdfdownload/8052240.pdf.

  18. Institute of Medicine. Report from the Committee on Advancing Pain Research, Care, and Education: relieving pain in America, a blueprint for transforming prevention, care, education and research. Washington, DC: The National Academies Press; 2011.

    Google Scholar 

  19. Pradip et al. Associations of nonmedical pain reliever use and initiation of heroin use in the U.S. center for behavioral health statistics and quality data review. SAMHSA (2013) http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.htm

  20. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17(6):372–87.

    Google Scholar 

  21. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–75.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain. 2004;109(3):514–19.

    Article  PubMed  Google Scholar 

  23. IMS Health, Vector One: National, years 1991-1996, Data Extracted 2011. IMS Health, National Prescription Audit, years 1997-2013, Data Extracted 2014.

    Google Scholar 

  24. Califano JA. High society: how substance abuse ravages America and what to do about it. New York: Perseus; 2007.

    Google Scholar 

  25. Chou R, Huffman L. Use of chronic opioid therapy in chronic non-cancer pain: evidence review. Glenview: American Pain Society; 2009.

    Google Scholar 

  26. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297:249–51.

    CAS  PubMed  Google Scholar 

  27. Pain and Policy Studies Group. International Narcotics Control Board opioid consumption data. http://www.painpolicy.wisc.edu/opioid-consumption-data. Accessed April 13, 2015.

  28. Volkow, ND. Director, National Institute on Drug Abuse, National Institutes of Health, U.S. Department of Health and Human Services, before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources Committee, July 26, 2006.

    Google Scholar 

  29. U.S. Department of Health and Human Services. Addressing prescription drug abuse in the United States: current activities and future opportunities. 2013. http://www.cdc.gov/HomeandRecreationalSafety/pdf/HHS_Prescription_Drug_Abuse_Report_09.2013.pdf Accessed April 12, 2015

  30. Krüger R, Meißner W, Zimmer A. Misuse of opioid analgesics. An Internet analysis. Schmerz. 2014;28(5):473–82.

    Article  PubMed  Google Scholar 

  31. Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24(6):528–35.

    Article  PubMed  Google Scholar 

  32. Vietri J, Joshi AV, Barsdorf AI, Mardekian J. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15(12):2064–74.

    Article  PubMed  Google Scholar 

  33. Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM, Ross S, Gerhard GS, Stewart WF. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011;30(3):185–94.

    Article  PubMed  Google Scholar 

  34. Cheatle MD, O’Brien CP, Mathai K, Hansen M, Grasso M, Yi P. Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids. J Opioid Manag. 2013;9(5):315–24.

    Article  PubMed  Google Scholar 

  35. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003;4:340–51.

    Article  PubMed  Google Scholar 

  36. Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilliday BB, DeWalt DA, Pignone MP. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46–56.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Macey TA, Morasco BJ, Duckart JP, Dobscha SK. Patterns and correlates of prescription opioid use in OEF/OIF veterans with chronic noncancer pain. Pain Med. 2011;12(10):1502–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry. 2008;30:93–9.

    Article  PubMed  Google Scholar 

  39. Palmer R, Carrell D, Cronkite D, Saunders K, Gross D, Masters E, Hylan T, VonKroff M The prevalence and characteristics of patients with indicators of opioid abuse within an integrated group practice. Presented at the American Pain Society 33rd Annual Scientific Meeting; April 30-May 3, 2014. Tampa, FL. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM397249.pdf.

  40. Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage. 2011;41:116–25.

    Article  CAS  PubMed  Google Scholar 

  41. Proctor SL, Estroff TW, Empting LD, Shearer-Williams S, Hoffmann NG. Prevalence of substance use and psychiatric disorders in a highly select chronic pain population. J Addict Med. 2013;7(1):17–24.

    Article  PubMed  Google Scholar 

  42. Sowa EM, Fellers JC, Raisinghani RS, Santa Cruz MR, Hidalgo PC, Lee MS, Martinez LA, Keller AE, Clayton AH. Prevalence of substance misuse in new patients in an outpatient psychiatry clinic using a prescription monitoring program. Prim Care Companion CNS Disord. 2014;16(1).

    Google Scholar 

  43. Belgrade MJ, Ismail M, Yoon M, Panopoulos G. Non-compliant drug screens during opioid maintenance analgesia for chronic non-malignant pain. Am Pain Society Meeting, 2001. San Diego A# 787, p. 42.

    Google Scholar 

  44. Couto JE, Romney MC, Leider HL, Sharma S, Goldfarb NI. High rates of inappropriate drug use in the chronic pain population. Popul Health Manag. 2009;12:185–90.

    Article  PubMed  Google Scholar 

  45. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9:123–9.

    PubMed  Google Scholar 

  47. Manchikanti L, Manchukonda R, Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician. 2005;8:257–61.

    PubMed  Google Scholar 

  48. Michna EJ, Ross EL, Janfaza D, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23:173–9.

    Article  PubMed  Google Scholar 

  49. Vaglienti RM, Huber SJ, Noel KR, Johnstone RE. Misuse of prescribed controlled substances defined by urinalysis. W V Med J. 2003;99:67–70.

    PubMed  Google Scholar 

  50. Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med. 2007;8:647–56.

    Article  PubMed  Google Scholar 

  51. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage. 2008;36(3):280–8.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Meyer C, Rumpf H, Hapke U, Dilling H, John U. Lebenszeitpra¨valenz psychicher störungen in der erwachsenen allgemeinbevölkerung [Lifetime prevalence of mental disorders in general adult populations. Results of TACOS study]. Nervenarzt. 2000;71:535–42.

    Article  CAS  PubMed  Google Scholar 

  53. Regier D, Farmer M, Rae D, Locke Z, Keith S, Judd L, Goodwin F. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;19:2511–8.

    Article  Google Scholar 

  54. Wilsey BL, Fishman SM, Tsodikov A, Ogden C, Symreng I, Ernst A. Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Med. 2008;9(8):1107–17.

    Article  PubMed  Google Scholar 

  55. Butler SF, Budman SH, Licari A, et al. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–54.

    Article  PubMed  Google Scholar 

  56. Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the Current Opioid Misuse Measure (COMM) to monitor chronic pain patients on opioid therapy. Clin J Pain. 2010;26:770–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Cicero TJ, Surratt H, Inciardi JA, et al. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16:827–40.

    Article  CAS  PubMed  Google Scholar 

  58. Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008;139(1):127–35.

    Article  PubMed  Google Scholar 

  59. Katz N, Panas L, Kim M, et al. Usefulness of prescription monitoring programs for surveillance—analysis of schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiol and Drug Saf. 2010;19:115–23.

    Article  Google Scholar 

  60. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Measurement of opioid problems among chronic pain patients in a general medical population. Drug Alcohol Depend. 2009;104(1-2):43–9.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Office of National Drug Control Policy. Arrestee Drug Abuse Monitoring Program II, 2013 Annual Report; https://www.whitehouse.gov/sites/default/files/ondcp/policy-andresearch/adam_ii_2013_annual_report.pdf

  62. Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol. 2007;45:144–51.

    Article  Google Scholar 

  63. U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System (NFLIS). 2013 Annual Report. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS2013AR.pdf. Accessed April 12, 2015

  64. Woody GE, Senay EC, Geller A, Adams EH, Inciardi JA, Schnoll S, Muñoz A, Cicero TJ.An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend. 2003;72(2):163–8.

    Google Scholar 

  65. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76.

    Article  PubMed  Google Scholar 

  66. Portenoy R. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11:203–17.

    Article  CAS  PubMed  Google Scholar 

  67. Jaffee J. Opiates: clinical aspects. In: Lowenson J, Ruiz P, Mullman R, editors. Substance abuse, a comprehensive text. Baltimore: Williams & Wilkins; 1992. p. 186–94.

    Google Scholar 

  68. Lowinson JH, Ruiz P, Milman RB. Substance abuse: a comprehensive textbook. Baltimore: Williams & Wilkins; 1992.

    Google Scholar 

  69. Wasan A, Correll D, Kissin I, O’Shea S, Jamison R. Iatrogenic addiction in patients treated for acute or subacute pain: a systematic review. J Opioid Manage. 2006;2:16–22.

    Google Scholar 

  70. Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: A review. Pain Med. 2002;3:260–71.

    Article  CAS  PubMed  Google Scholar 

  71. Aronoff G. Opioids in chronic pain management: is there a significant risk of addiction? Curr Rev Pain. 2000;4:112–21.

    Article  CAS  PubMed  Google Scholar 

  72. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490–518.

    Google Scholar 

  73. Martell B, O’Connor P, Kerns R, Becker W, Morales K, Kosten T, Fiellin D. Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:187–92.

    Article  Google Scholar 

  74. Sullivan M. Clarifying opioid misuse and abuse. Pain. 2013;154:2239–40.

    Article  PubMed  Google Scholar 

  75. Cooper HM. Synthesizing research: a guide for literature reviews. 3rd ed. Newbury Park: Sage; 2001.

    Google Scholar 

  76. Hemingway P, Brereton N. What is a systematic review? Evidenced-based medicine. http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/syst-review.pdf. Accessed April 15, 2015

  77. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444–59.

    Article  PubMed  Google Scholar 

  78. Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O’Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013; 154: 2287–96.

    Google Scholar 

  79. Kotecha MK, Sites BD. Pain policy and abuse of prescription opioids in the USA: a cautionary tale for Europe. Anethesia. 2013;68:1207–19.

    Article  Google Scholar 

  80. Muhuri PK, Gfroerer JC, Davies MC. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHDQ Data Review. Rockville, MD: Substance Abuse and Mental Health Services Administration. http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf. Accessed April 27, 2014.

  81. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479–91.

    PubMed  Google Scholar 

  82. Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD. Prescribing opioids for chronic noncancer pain in primary care: risk assessment. Postgrad Med. 2014;126(5):159–66.

    Article  PubMed  Google Scholar 

  83. Huffman KL, Shella ER, Sweis G, Griffith SD, Scheman J, Covington EC. Nonopioid substance use disorders and opioid dose predict therapeutic opioid addiction. J Pain. 2015;16(2):126–34.

    Article  PubMed  Google Scholar 

  84. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67–92.

    PubMed  Google Scholar 

  85. American Academy of Pain Medicine. Use of opioids for the treatment of chronic pain: A statement from the American Academy of Pain Medicine. 2013. http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf. Accessed April 15, 2015.

Download references

Acknowledgment

Financial support for the preparation of this chapter was provided by the NIDA grants: DA030446 to JDJ, DA016759 to SDC.

Author information

Authors and Affiliations

  1. Division on Substance Abuse, New York Psychiatric Institute and Columbia University Medical Center, New York, NY, USA

    Jermaine D. Jones Ph.D. & Sandra D. Comer

Authors
  1. Jermaine D. Jones Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra D. Comer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jermaine D. Jones Ph.D. .

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Department of Psychiatry, Portland, Oregon, USA

    Annette M. Matthews

  2. Maine Medical Center, Department of Psychiatry, Portland, Oregon, USA

    Jonathan C. Fellers

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jones, J.D., Comer, S.D. (2016). The Epidemiology of Pain and Opioid Abuse. In: Matthews, A., Fellers, J. (eds) Treating Comorbid Opioid Use Disorder in Chronic Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-29863-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29863-4_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29861-0

  • Online ISBN: 978-3-319-29863-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation